Our global manufacturing network enables us to efficiently deliver individualized CAR T-cell therapies to patients worldwide. With centralized operations and in-house expertise, we work every day to help ensure consistent, high-quality treatments reach eligible patients.? ? #CellTherapy | #CARTcell?
Kite Pharma
生物技术研究
Santa Monica，California 152,470 位关注者
At Kite, a Gilead Company, our singular focus is cell therapy to treat and cure cancer.
关于我们
At Kite, a Gilead Company, our singular focus is achieving cures with cell therapy. Our goal is to bring the promise of cell therapy to as many eligible patients as possible who may benefit. Since 2009, Kite has been at the forefront of cancer immunotherapy. Today, we are proud to be the leader in engineered T cell therapy for hematologic malignancies, but we recognize that this is just the beginning. Patients are at the heart of our focus on the cure, which is why we are committed to pursuing cell therapy as a transformative treatment option for as many people with cancer as possible who may benefit. Cancer is personal to us. Unlike traditional pharmaceutical manufacturing, our therapies are not created on an assembly line. Cell therapy specialists at our manufacturing facilities reengineer a patient’s own immune cells to attack and fight their cancer cells — one patient at a time. That sense of connection to the people we serve motivates us daily at Kite. Our corporate headquarters are located in Santa Monica, California, and we have dedicated cell therapy manufacturing facilities in California, Maryland and the Netherlands. If you’re passionate about changing the future of cancer treatment, let’s talk. See our community guidelines: https://bit.ly/2DznMNw
- 网站
-
https://www.kitepharma.com
Kite Pharma的外部链接
- 所属行业
- 生物技术研究
- 规模
- 1,001-5,000 人
- 总部
- Santa Monica，California
- 类型
- 上市公司
- 创立
- 2009
- 领域
- Cancer Treatment、Engineered Autologous Cell Therapy (eACT)、Immunotherapy、T-Cells和cell therapy
地点
Kite Pharma员工
动态
-
We’re attending the ISPOR—The Professional Society for Health Economics and Outcomes Research Europe 2024 congress in Spain. This event brings together experts from around the world to drive scientific progress. We’re proud to present eight abstracts from seven countries as part of our ongoing commitment to changing the way blood cancer is treated. #ISPOREurope | #CellTherapy
-
-
This Veterans Day, we honor all who served, including William, a veteran who battled cancer with help from his care team at the Veterans Affairs Medical Center in Nashville. His inspiring story is featured in the 2024 issue of Armed Forces Medicine.? ? #VeteransDay | #SupportOurVeterans?
-
#KiteNews: We’re presenting the latest data and real-world analyses from our CAR T-cell therapy portfolio at the American Society of Hematology Annual Meeting 2024, underscoring our commitment to patients with a spectrum of blood cancers. Our partner Arcellx will share preliminary results from the Phase 1 study in addition to the Phase 2 registrational study of CAR T-cell therapy in relapsed/refractory multiple myeloma. #ASH24 Read more: https://bit.ly/48JfZdN
-
-
Our team gathered in Los Angeles for #LightTheNight?to celebrate the strength of the blood cancer community. Gilead and Kite Oncology proudly support The Leukemia & Lymphoma Society as the event's National Presenting Sponsor of Celebration and Community, holding our lanterns high to help bring light to the darkness of cancer.?
-
As a Sample Management Supervisor, working in quality control feels very personal to Guadalupe Gonzalez. She knows that each sample she coordinates represents an individualized treatment for a patient. #celltherapy?
-
-
Our top priority at Kite is?helping to ensure that every patient who can benefit from CAR T-cell therapy has access to it, and our global manufacturing network is central to how we deliver CAR T to patients.?? ? #CellTherapy | #CARTcell?
-
We’re pleased to announce that Kite has appointed Gallia Levy, MD, PhD, as Global Head of Clinical Development and Laura Alquist as Global Head of Technical Operations, following Chris McDonald’s retirement at the end of this year.
-
-
This #WorldInclusionDay, we’re highlighting colleagues who champion inclusion, drive innovation and create a more connected environment. Our Employee Resource Groups (ERG) play a key role, and we’re proud to announce the launch of our new Disability Inclusion ERG, creating a community for employees living with disabilities. Together with Gilead Sciences, we’re fostering a culture where everyone belongs. #GileadLife #PassThePhoneChallenge
-
We look forward to connecting with the #celltherapy community and sharing our latest research at the APBMT 2024 Annual Meeting in Singapore this weekend. #APBMT2024
-